Brokerages Set Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) PT at $11.00

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $11.00.

A number of equities analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Evaxion A/S in a research note on Monday, March 9th. Lake Street Capital dropped their target price on Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Monday, March 9th. Maxim Group started coverage on Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 price target on the stock. Wall Street Zen lowered Evaxion A/S from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a research note on Friday, January 9th.

Institutional Trading of Evaxion A/S

A number of institutional investors have recently modified their holdings of the company. SmartHarvest Portfolios LLC purchased a new position in shares of Evaxion A/S in the 4th quarter worth approximately $72,000. Wesbanco Bank Inc. purchased a new stake in Evaxion A/S during the fourth quarter valued at approximately $48,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in Evaxion A/S in the fourth quarter valued at approximately $38,000. 11.04% of the stock is currently owned by institutional investors.

Evaxion A/S Trading Down 4.1%

NASDAQ:EVAX opened at $3.78 on Tuesday. The firm has a 50-day simple moving average of $3.51 and a 200-day simple moving average of $4.72. Evaxion A/S has a one year low of $1.20 and a one year high of $12.15. The firm has a market cap of $31.53 million, a P/E ratio of -2.86 and a beta of 0.19. The company has a debt-to-equity ratio of 0.41, a quick ratio of 5.85 and a current ratio of 5.85.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.